This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Emrosi’s approval was based on data from a pair of Phase III clinicaltrials for the treatment of rosacea. The trials met all co-primary and secondary endpoints, with participants having successfully completed the 16-week treatment with no significant safety issues.
The US Food and Drug Administration has approved a fast-acting nasal spray from Pfizer designed to treat migraines, the US pharmaceutical giant said Friday.
The FDAapproval is based on findings from the multicentre Phase II CENTAUR clinicaltrial that enrolled 137 ALS patients. For the first three weeks, the recommended dose is one packet a day. Following this time period, the dosage is raised to one packet twice daily.
Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.
Yesafili and Opuviz are approved to treat the same conditions as Regeneron’s vascular endothelial growth factor (VEGF) inhibitor Eylea — neovascular (wet) age-related macular degeneration (AMD), diabetic retinopathy, macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME). According to Biocon, there are 19.8
On Thursday, the FDA granted De Novo authorization for NeuroMetrix to market the Quell® wearable neuromodulation device for treating fibromyalgia. This approval is significant because prior to Quell, there were no FDA-approved medical devices for fibromyalgia treatment.
This translates to an average weight loss of 21%, which was demonstrated in clinicaltrials (over a period of 72 weeks) that supported Zepbounds FDAapproval. This month, Zepbound won FDAapproval for obstructive sleep apnea (OSA) , making it the first approved drug for the condition.
Related: Arrowhead Pharmas New Rare Disease Campaign for FCS Highlights Importance of Lowering Triglycerides The FDAsapproval of Crenessity was based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic CAH.
Roche is hoping to undercut hugely expensive rivals after the FDAapproved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). The FDAapproved Evrysdi for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.
Amneal Pharmaceuticals and Shilpa Medicare have announced US Food and Drug Administration (FDA) approval of Boruzu, a ready-to-use formulation of bortezomib for subcutaneous or intravenous (IV) administration. This will help healthcare providers seamlessly incorporate this ready-to-use solution into their clinical practice.
The US Food and Drug Administration (FDA) has given the nod to Winrevair (sotatercept-csrk injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO (World Health Organization) functional class (FC) and reduce the risk of clinical worsening events.
It also marks the first US approval for an oral penem antibiotic (a class of beta-lactam antibiotics with wide-ranging antibacterial activity). Orlynvah is also only the second uUTI treatment approved in the past two decades. Orlynvah was generally well tolerated in both SURE 1 and REASSURE clinicaltrials.
It also marks the first US approval for an oral penem antibiotic (a class of beta-lactam antibiotics with wide-ranging antibacterial activity). Orlynvah is also only the second uUTI treatment approved in the past two decades. Orlynvah was generally well tolerated in both SURE 1 and REASSURE clinicaltrials.
Eichenfield serves on Verrica Pharmaceuticals’ Board of Directors and spoke to Xtalks about the company’s recent approval of YCANTH (cantharidin) topical solution as the first FDAapproved treatment for pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection that primarily affects children.
Verona Pharma has received US Food and Drug Administration (FDA) approval for Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disorder (COPD). After Jack, Verona was established to take on ensifentrine and 19 years and almost 20 clinicaltrials later, the drug has finally received its approval.
Pricing data indicate that the price of TNKase is around $8,672 for a 50 mg IV injection for cash-paying customers, though prices can vary based on pharmacy and location. XTALKS WEBINAR: Rethinking Recruitment and Retention with Empathy and Innovation: What if Patients Chose You?
Now available with two administration options, FluMist can be administered either by a healthcare professional in a clinical setting or by the vaccine recipient or caregiver at home. The FDA’s approval came after comprehensive studies, which included human factors and usability evaluations.
A good portion of this blog takes on Big Pharma for their funding of misleading public information campaigns and programs against drug importation and the practice of safe international online pharmacies. Longer and more involved clinicaltrials are still necessary for the drug to obtain full approval.
Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDAapproval process. .
Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDAapproval in 2002. This initial approval was only for treatment of excessive daytime sleepiness. Wake up and go to sleep.
KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinicaltrials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. Samsung Biologics (KRX: 207940.KS)
Why it sold so well: Botox is FDA-approved for the treatment of chronic migraines and that is currently the only chronic condition for which it has received approval. mL, depending on the pharmacy. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. mL) is around $620 for a supply of 0.25
FDAApproves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies. The increase in survival observed with Zokinvy was derived from two open-label clinicaltrials (N=62) conducted at Boston Children’s Hospital. PALO ALTO, Calif., Outside the U.S.,
Melanie Blank, clinical team leader for General Medicine Branch 1 at the US Food and Drug Administration’s (FDA) Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), the agency is seeing one or two new applications coming in every week for new gene therapies for different diseases. Reference: Chung DC, et al.
Initially receiving accelerated approval in December 2021 based on proteinuria as a surrogate marker, Tarpeyo has now achieved the status of being the first treatment for IgAN to receive full FDAapproval predicated on evaluations of kidney function.
As the second wave of the pandemic continues to grip much of the world, the study is part of efforts to identify existing FDA-approved drugs that can be repurposed to treat or prevent COVID-19 as it is the most efficient and inexpensive approach. The list also included melatonin.
In time for respiratory virus season this fall and winter, the US Food and Drug Administration (FDA) approved updated COVID vaccines from Pfizer/BioNTech and Moderna last week, followed by an endorsement from the Centers for Disease Control and Prevention (CDC) a day later.
Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDAapproval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5 Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics.
The growth is attributed to regulatory approvals, strategic partnerships and the acquisitions of innovative medical technology companies. Additionally, Abbott launched over 125 new products in 2022, in conjunction with a series of FDAapprovals. The company reported an investment of $2.7 billion ($22.83 billion USD), a 20.65
To celebrate this milestone, we’re taking a look back over the last 20 years in the pharmaceutical industry by highlighting some of the most talked-about mergers, blockbuster drugs, trends in FDAapprovals and what’s next. Just last year, the FDAapproved a one-time gene therapy treatment for hemophilia B priced at $3.5
MUSC Hollings Cancer Center part of promising clinicaltrial for aggressive lymphoma. MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. Original Source.
Opponents of Americans buying less expensive drugs from overseas pharmacies (i.e. The two agencies almost always agree on which drugs should be approved, although there is some dialog of a potential growing divergence. drug regulatory system, see: How FDAApproves Drugs and Regulates Their Safety and Effectiveness.
of the US Importation Rule, drugs eligible for importation must have received an NOC and DIN in Canada and meet FDAapproval conditions, aside from US labeling. Interim Order Respecting ClinicalTrials for Medical Devices and Drugs Relating to COVID-19 (signed May 23, 2020). Interim Order Context.
Samsung Bioepis was the first company to receive FDAapproval for both high-concentration and low-concentration formulations of adalimumab biosimilar. However, it is important for all stakeholders to realize that the FDA interchangeability designation is a legal distinction, not a clinical one.
The webinar also featured Kelsey Carter, MS, ClinicalTrial Manager at Medpace who discussed the site, operational and regulatory challenges for neuroscience trials with direct CNS administration along with the strategies to mitigate these challenges. Figure 3 ). Targeting the CNS directly has been successful in modern medicine.
The stability at refrigerated conditions allows for storage at most pharmacies, hospitals, or physicians’ offices. No Dilution Required at Vaccination Site: The vaccine will not require onsite dilution or special handling, which facilitates vaccination across a range of settings including pharmacies and physicians’ offices.
Related: Sebetralstat Gets NDA Accepted by FDA for Hereditary Angioedema Miplyffa was initially turned down by the FDA back in 2021. That submission was accompanied by data from just one clinicaltrial that used a different measure of disease severity known as the 5-domain NPC Clinical Severity Scale (5DNPCCSS).
We are encouraged that no variants resistant to the cocktail were identified in the clinicaltrial analyses to date, which is consistent with our preclinical findings. Casirivimab and imdevimab have not been approved by FDA and remain investigational. Data from these trials will be used to support a future BLA submission.
COVID-19 vaccines have been a topic of conversation since the outbreak began, and last year’s US Food and Drug Administration (FDA) approval of the Pfizer/BioNTech and Moderna vaccines have given the world hope to defeat the COVID-19 pandemic. The safety of the vaccines is continuously monitored.”.
If REGN-COV2 proves safe and effective in clinicaltrials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. Department of Health and Human Services under OT number: HHSO100201700020C. Regeneron has partnered with Roche to increase the global supply of REGN-COV2 beginning in 2021.
baricitinib has not been approved by the FDA to treat COVID-19, and the efficacy, safety and optimal duration of treatment of baricitinib for COVID-19 has not been established. Evaluation of baricitinib’s efficacy and safety as a treatment for COVID-19 is ongoing in clinicaltrials. It is approved in the U.S.
“Patients in our antibody cocktail outpatient clinicaltrial experienced significant reductions in virus levels and required fewer medical visits for COVID-19, suggesting the therapy can help reduce the current burden on hospitals and healthcare systems,” said George D.
Data from the Phase 1/2/3 clinicaltrial supported an Emergency Use Authorization for casirivimab and imdevimab administered together, granted by the U.S. If the therapy proves safe and effective in clinicaltrials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. ,
NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinicaltrial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. Evaluation of its safety and efficacy is ongoing in multiple clinicaltrials. In the U.S.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content